{"id":892625,"date":"2025-10-06T09:51:31","date_gmt":"2025-10-06T13:51:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/"},"modified":"2025-10-06T09:51:31","modified_gmt":"2025-10-06T13:51:31","slug":"broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/","title":{"rendered":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon"},"content":{"rendered":"

<\/p>\n

Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon<\/b><\/p>\n

Contends There Is No Business Justification for the Board\u2019s Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year<\/i><\/b><\/p>\n

Encourages Shareholders to Vote \u201cAGAINST<\/span>\u201d the Proposed Acquisition<\/i><\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nBroadwood Partners, L.P. and its affiliates (collectively, \u201cBroadwood\u201d) today issued the following letter to the Board of Directors (the \u201cBoard\u201d) of STAAR Surgical Company (\u201cSTAAR\u201d or the \u201cCompany\u201d) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR\u2019s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN<\/span><\/b> Proxy Card \u201cAGAINST<\/span><\/b>\u201d the proposed acquisition of STAAR by Alcon Inc. (\u201cAlcon\u201d) (NYSE: ALC).<\/p>\n

\nShareholders can find additional information at www.LetSTAARShine.com<\/a>.<\/p>\n

\nOctober 6, 2025<\/p>\n

\nSTAAR Surgical Company
\n
25510 Commercentre Dr.
\n
Lake Forest, CA 92630<\/p>\n

\nDear Members of the Board:<\/p>\n

\nYou have decided it is time to sell STAAR for $28<\/span> per share. As you know, we strongly disagree with that decision.<\/p>\n

\nOne thing we can surely agree on, however, is that this Board is, at best, one-for-two in making decisions about selling STAAR. With hundreds of millions of dollars of shareholder money at stake, that is not good enough.<\/p>\n

\nSixteen months ago, you decided not<\/span> to sell the Company to Alcon for $58<\/span> per share in cash. You walked away from the table because of your belief in STAAR\u2019s strong business prospects.1<\/sup> Yet now, with little change in the market, management\u2019s financial forecasts, or STAAR\u2019s opportunities, you have decided to sell the Company for $28 per share.<\/p>\n

\n\u201cNo\u201d to $58.<\/p>\n

\n\u201cYes\u201d to $28.<\/p>\n

\nAs your largest shareholder, we believe the Board got it right the first time.<\/p>\n

\nThe Board wants shareholders to believe that its decision to sell the Company now, at less than half the price, was based on a reassessment of the Company\u2019s business performance and outlook. But we cannot fathom how that could be.<\/p>\n

\nThe Company had a difficult few quarters, to be sure, as demand in China slowed temporarily and excess inventory was worked off. But now, STAAR\u2019s prospects are sound, with sufficient cash, strong demand, new products ready to be launched, and cost savings opportunities to drive future profitability. In fact, if management\u2019s own projections are achieved, the company will experience double-digit revenue growth and profit margins that are among the highest of any midsized medical technology company in the world. And those projections are consistent with the company\u2019s prospects at the time you rejected $58 per share.<\/p>\n

\nWe can only assume that the Board does not believe in this management\u2019s latest forecast. But shareholders have no reason to trust your assessment of the future. When you decided not to sell for $58 per share, for example, you evidently did not foresee the transitory troubles in China that would occur six months later. If you could not foresee a problem that was mere months away \u2013 and one that you now claim caused a collapse of enterprise value by more than 50% \u2013 why should any investor rely on your judgment or foresight today?<\/p>\n

\nWe continue to believe the business is far more valuable than $28 per share and the Company\u2019s prospects are as bright as ever. We are disappointed with your one-for-two track record, which inspires no confidence.<\/p>\n

\nFor these reasons, we will vote against this transaction and are encouraging<\/a> our fellow shareholders to vote \u201cAGAINST<\/span><\/b>\u201d the deal too. When they do so, we believe shareholders will next need to address the poor judgment you have exhibited and consider how trust in the Company, its management team, and directors can be rebuilt and STAAR\u2019s bright prospects can be realized.<\/p>\n

\nSincerely,<\/p>\n

\nNeal Bradsher
\n
Founder and President
\n
Broadwood Capital, Inc., General Partner of Broadwood Partners, L.P.<\/p>\n

About Broadwood<\/b><\/p>\n

\nBroadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.<\/p>\n

Certain Information Concerning the Participants<\/b><\/p>\n

\nBroadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the \u201cParticipants\u201d) are participants in the solicitation of proxies from the shareholders of STAAR in connection with the special meeting of shareholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the \u201cSpecial Meeting\u201d). The Participants have filed a definitive proxy statement on Schedule 14A (the \u201cDefinitive Proxy Statement\u201d) and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company\u2019s shareholders for the Special Meeting. SHAREHOLDERS OF STAAR ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE \u201cSEC\u201d) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of STAAR\u2019s shareholders and will be, along with other relevant documents, available at no charge on the SEC\u2019s website at https:\/\/www.sec.gov\/<\/a>.<\/p>\n

\nInformation about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on September 26, 2025 and is available here<\/a>.<\/p>\n\n\n\n
_________________<\/td>\n<\/tr>\n
\n

1<\/sup> Source: STAAR proxy statement on Form DEFM14A, filed with the SEC on September 16, 2025.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251005004584\/en\/<\/a><\/span><\/p>\n

Investor Contacts
\n<\/b>
John Ferguson \/ Joseph Mills
\n
Saratoga Proxy Consulting LLC
\n
jferguson@saratogaproxy.com
\n<\/a>
jmills@saratogaproxy.com
\n<\/a>
(212) 257-1311
\n
(888) 368-0379<\/p>\n

Media Contacts
\n<\/b>
Scott Deveau \/ Jeremy Jacobs
\n
August Strategic Communications
\n
Broadwood@AugustCo.com
\n<\/a>
(323) 892-5562<\/p>\n

KEYWORDS:<\/b> United States North America New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Medical Devices Health Surgery Finance Optical<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon Contends There Is No Business Justification for the Board\u2019s Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year Encourages Shareholders to Vote \u201cAGAINST\u201d the Proposed Acquisition NEW YORK–(BUSINESS WIRE)– Broadwood Partners, L.P. and its affiliates (collectively, \u201cBroadwood\u201d) today issued the following letter to the Board of Directors (the \u201cBoard\u201d) of STAAR Surgical Company (\u201cSTAAR\u201d or the \u201cCompany\u201d) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR\u2019s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card \u201cAGAINST\u201d the proposed acquisition of STAAR by Alcon Inc. (\u201cAlcon\u201d) (NYSE: ALC). Shareholders … <\/p>\n

Continue reading “Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBroadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon Contends There Is No Business Justification for the Board\u2019s Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year Encourages Shareholders to Vote \u201cAGAINST\u201d the Proposed Acquisition NEW YORK–(BUSINESS WIRE)– Broadwood Partners, L.P. and its affiliates (collectively, \u201cBroadwood\u201d) today issued the following letter to the Board of Directors (the \u201cBoard\u201d) of STAAR Surgical Company (\u201cSTAAR\u201d or the \u201cCompany\u201d) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR\u2019s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card \u201cAGAINST\u201d the proposed acquisition of STAAR by Alcon Inc. (\u201cAlcon\u201d) (NYSE: ALC). Shareholders … Continue reading "Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T13:51:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon\",\"datePublished\":\"2025-10-06T13:51:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/\"},\"wordCount\":1013,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/\",\"name\":\"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-06T13:51:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/","og_locale":"en_US","og_type":"article","og_title":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk","og_description":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon Contends There Is No Business Justification for the Board\u2019s Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year Encourages Shareholders to Vote \u201cAGAINST\u201d the Proposed Acquisition NEW YORK–(BUSINESS WIRE)– Broadwood Partners, L.P. and its affiliates (collectively, \u201cBroadwood\u201d) today issued the following letter to the Board of Directors (the \u201cBoard\u201d) of STAAR Surgical Company (\u201cSTAAR\u201d or the \u201cCompany\u201d) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR\u2019s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card \u201cAGAINST\u201d the proposed acquisition of STAAR by Alcon Inc. (\u201cAlcon\u201d) (NYSE: ALC). Shareholders … Continue reading \"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-06T13:51:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon","datePublished":"2025-10-06T13:51:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/"},"wordCount":1013,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/","name":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-06T13:51:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251005004584r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/broadwood-partners-issues-letter-to-staar-surgicals-board-questioning-its-judgment-in-proposed-sale-to-alcon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Broadwood Partners Issues Letter to STAAR Surgical\u2019s Board Questioning Its Judgment in Proposed Sale to Alcon"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}